Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18370780 | 0.95 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP3A4ALOX15KDM4E | |
| SCHEMBL4988910 | 0.86 | HSD17B10 (0.55) | ALDH1A1MAPTCYP3A4ALOX15KDM4E | |
| SCHEMBL1094404 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTCYP3A4ALOX15KDM4E | |
| SCHEMBL27759780 | 0.84 | KDM4A (0.41) | ALDH1A1MAPTCYP3A4ALOX15VCAM1 | |
| SCHEMBL9052138 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPTCYP3A4ALOX15KDM4E | |
| SCHEMBL5583374 | 0.81 | VCAM1 (0.55) | ALDH1A1MAPTCYP3A4ALOX15KDM4E | |
| SCHEMBL138641 | 0.80 | TDP1 (0.50) | ALDH1A1MAPTCYP3A4ALOX15VCAM1 | |
| SCHEMBL30953155 | 0.80 | TDP1 (0.50) | ALDH1A1MAPTCYP3A4ALOX15VCAM1 | |
| SCHEMBL9694173 | 0.80 | TSHR (0.50) | ALDH1A1MAPTCYP3A4ALOX15VCAM1 | |
| SCHEMBL13527036 | 0.80 | HSD17B10 (0.53) | ALDH1A1MAPTCYP3A4ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493559-A | Preparation and application of cyclized indigo receptor and polymer | 中国科学院化学研究所 | 2021-10-12 | — | — | CN | claimed |
| JP-8268974-A | — | — | None | — | — | JP | disclosed |
| CN-113493559-A | Preparation and application of cyclized indigo receptor and polymer | 中国科学院化学研究所 | 2021-10-12 | — | — | CN | disclosed |
| EP-3196189-B1 | METHOD FOR PRODUCING 2-AMINO-SUBSTITUTED BENZALDEHYDE COMPOUND | NIPPON SODA CO (JP) | 2020-09-23 | — | — | EP | disclosed |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170226046-A1 | METHOD FOR PRODUCING 2-AMINO-SUBSTITUTED BENZALDEHYDE COMPOUND | NIPPON SODA CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3196189-A1 | METHOD FOR PRODUCING 2-AMINO-SUBSTITUTED BENZALDEHYDE COMPOUND | Nippon Soda Co., Ltd. (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9493459-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-1824856-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | disclosed |
| US-20070078132-A1 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | JANSSEN-CILAG (FR) | 2007-04-05 | — | — | US | disclosed |
| CN-1894260-A | Pyridopyrimidines and pyrimidopyrimidine derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-10 | — | — | CN | disclosed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| CN-1794996-A | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA NV (BE) | 2006-06-28 | — | — | CN | disclosed |
| WO-2006061415-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061417-A2 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-15 | — | — | WO | disclosed |
| EP-1633365-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105765-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
| JP-H08268974-A | 3-FLUORO-4-CHLORO-6-NITROBENZALDEHYDE, 3-FLUORO-4-CHLORO-6-NITROBENZALDEHYDE ACETAL AND THEIR PRODUCTION | UBE IND LTD | 1996-10-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078132-A1 | tyrosine kinase inhibitors such as 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro, used for treating hyper proliferative disorders such as atherosclerosis, restenosis and cancer | NR1H3, NR1H2, ERBB2 | ALDH1A1 3804/4885MAPT 4874/4885CYP3A4 730/4885 |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | NR1H3, NR1H2, NCOA3 | ALDH1A1 2648/4885MAPT 4756/4885CYP3A4 112/4885 |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | ALDH1A1 2965/4885MAPT 4740/4885CYP3A4 177/4885 |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | NR1I3, NR3C2, NR1I2 | ALDH1A1 2965/4885MAPT 4740/4885CYP3A4 177/4885 |
| US-20170226046-A1 | METHOD FOR PRODUCING 2-AMINO-SUBSTITUTED BENZALDEHYDE COMPOUND | AZI2, DAO, ALKBH2 | ALDH1A1 96/4885MAPT 4774/4885CYP3A4 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.